Noxafil Is First FDA-Approved Antifungal For Aspergillus Infection Prevention
This article was originally published in The Pink Sheet Daily
Executive Summary
Schering-Plough plans to launch posaconazole for patients at high risk within two weeks.
You may also be interested in...
DOR Biopharma’s orBec For GI Disease Misses Primary Endpoint
Company is relying on “volume of evidence” showing clinical benefit to win FDA approval.
DOR Biopharma’s orBec For GI Disease Misses Primary Endpoint
Company is relying on “volume of evidence” showing clinical benefit to win FDA approval.
Schering-Plough Noxafil Review Prolonged By Last-Minute Label, Data Integrity Issues
FDA review documents for the antifungal illustrate an unusual case of the agency missing the user fee target for a priority review application.